March 6, 2017
International Journal of Drug Policy
We hear how well Licensed Producers (LP’s) are doing in the legal medical cannabis market, how stocks are going up, the market is expanding, and everything is rosy and fine. But there are many problems with the legal market that are being masked by the entrenched grey market. The proof is summarized in a paper entitled, “Medical Cannabis Access, Use, And Substitution For Prescription Opioids And Other Substances: A Survey Of Authorized Medical Cannabis Patients,” published recently in the International Journal of Drug Policy. (1)
Continue reading